Combination of granulocyte-monocyte apheresis and tofacitinib : Multicentre and retrospective study
Copyright © 2024 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved..
OBJECTIVE: Granulocyte-monocyte apheresis (GMA) has shown to be safe and effective in treating ulcerative colitis (UC), also in combination with biologics. The objective of this study is to evaluate the efficacy and safety of combining GMA after primary non-response (PNR) or loss of response (LOR) to tofacitinib (TOFA) in patients with UC.
PATIENTS AND METHODS: Retrospective study including all patients with refractory UC who received GMA plus TOFA. Efficacy was assessed 1 and 6 months after finishing GMA by partial Mayo score, C-reactive protein (CRP) and fecal calprotectin (FC). Descriptive statistics and non-parametric tests were used in the statistical analysis.
RESULTS: Twelve patients were included (median 46 years [IQR, 37-58]; 67% female; 67% E3). Patients were mostly receiving TOFA 10mg bid (75%), and 33% also concomitant steroids at baseline. Median partial Mayo score at baseline was 7 (IQR, 5-7), and it decreased to a median of 2 (IQR, 0-3) and 0 (IQR, 0-3) after 1 and 6 months (p=0.027 and 0.020, respectively), while no differences were found in CRP and FC. Clinical remission was achieved by 6 patients both at 1 (50%) and 6 months (67%). CF values<250mg/kg were achieved by 2 and 4 patients at 1 and 6 months (data available in 5 and 7 patients, respectively). No patient required dose-escalation of TOFA, and one patient was able to de-escalate the drug. No patient required colectomy and all patients under steroids were able to stop them.
CONCLUSION: The combination of GMA and TOFA can be effective in selected cases of UC after PNR or LOR to this drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - (2024) vom: 23. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodríguez-Lago, Iago [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aféresis de granulocitos-monocitos |
|---|
| Anmerkungen: |
Date Revised 15.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.gastrohep.2024.01.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367572397 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367572397 | ||
| 003 | DE-627 | ||
| 005 | 20240216232745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2024.01.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM367572397 | ||
| 035 | |a (NLM)38266817 | ||
| 035 | |a (PII)S0210-5705(24)00022-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodríguez-Lago, Iago |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination of granulocyte-monocyte apheresis and tofacitinib |b Multicentre and retrospective study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a OBJECTIVE: Granulocyte-monocyte apheresis (GMA) has shown to be safe and effective in treating ulcerative colitis (UC), also in combination with biologics. The objective of this study is to evaluate the efficacy and safety of combining GMA after primary non-response (PNR) or loss of response (LOR) to tofacitinib (TOFA) in patients with UC | ||
| 520 | |a PATIENTS AND METHODS: Retrospective study including all patients with refractory UC who received GMA plus TOFA. Efficacy was assessed 1 and 6 months after finishing GMA by partial Mayo score, C-reactive protein (CRP) and fecal calprotectin (FC). Descriptive statistics and non-parametric tests were used in the statistical analysis | ||
| 520 | |a RESULTS: Twelve patients were included (median 46 years [IQR, 37-58]; 67% female; 67% E3). Patients were mostly receiving TOFA 10mg bid (75%), and 33% also concomitant steroids at baseline. Median partial Mayo score at baseline was 7 (IQR, 5-7), and it decreased to a median of 2 (IQR, 0-3) and 0 (IQR, 0-3) after 1 and 6 months (p=0.027 and 0.020, respectively), while no differences were found in CRP and FC. Clinical remission was achieved by 6 patients both at 1 (50%) and 6 months (67%). CF values<250mg/kg were achieved by 2 and 4 patients at 1 and 6 months (data available in 5 and 7 patients, respectively). No patient required dose-escalation of TOFA, and one patient was able to de-escalate the drug. No patient required colectomy and all patients under steroids were able to stop them | ||
| 520 | |a CONCLUSION: The combination of GMA and TOFA can be effective in selected cases of UC after PNR or LOR to this drug | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aféresis de granulocitos-monocitos | |
| 650 | 4 | |a Colitis ulcerosa | |
| 650 | 4 | |a Enfermedad inflamatoria intestinal | |
| 650 | 4 | |a Granulocyte–monocyte apheresis | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Tofacitinib | |
| 650 | 4 | |a Ulcerative colitis | |
| 700 | 1 | |a Cañete, Fiorella |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra-Del-Río, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera-deGuise, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Leo, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Zabana, Yamile |e verfasserin |4 aut | |
| 700 | 1 | |a Barreiro-de Acosta, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Ginard, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Cabriada, José Luis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g (2024) vom: 23. Jan. |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2024.01.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 01 | ||